<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2529-850X</journal-id>
<journal-title><![CDATA[Journal of Negative and No Positive Results]]></journal-title>
<abbrev-journal-title><![CDATA[JONNPR]]></abbrev-journal-title>
<issn>2529-850X</issn>
<publisher>
<publisher-name><![CDATA[Research and Science S.L.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2529-850X2022000200004</article-id>
<article-id pub-id-type="doi">10.19230/jonnpr.4443</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Diabetes e insuficiencia cardiaca. ¿Son los inhibidores del cotransportador de sodioglucosa tipo dos el futuro del tratamiento?]]></article-title>
<article-title xml:lang="en"><![CDATA[Diabetes and heart failure. Are type two sodium-glucose cotransporter inhibitors the future of treatment?]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Almero-Ballesteros]]></surname>
<given-names><![CDATA[Beatriz]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Tarraga-Marcos]]></surname>
<given-names><![CDATA[Loreto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Madrona-Marcos]]></surname>
<given-names><![CDATA[Fatima]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Romero-de Avila]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[TárragaLópez]]></surname>
<given-names><![CDATA[Pedro J]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Facultad de Medicina de Albacete Departamento de Ciencias Medicas ]]></institution>
<addr-line><![CDATA[Albacete ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Almansa  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<volume>7</volume>
<numero>2</numero>
<fpage>209</fpage>
<lpage>234</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S2529-850X2022000200004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S2529-850X2022000200004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S2529-850X2022000200004&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción La diabetes mellitus es una enfermedad metabólica cuya incidencia y prevalencia van en aumento. Produce múltiples complicaciones tales como enfermedad aterosclerótica e insuficiencia cardiaca, siendo esta última, una de las principales causas de muerte. La diabetes mellitus puede desembocar en insuficiencia cardiaca a través de la miocardiopatía diabética. Para el tratamiento de la misma, destacan los inhibidores del cotransportador sodio-glucosa tipo 2 (iSGLT2), fármacos que actúan en el túbulo contorneado proximal renal.  Objetivos conocer el impacto de los iSGLT2 en el tratamiento de la diabetes mellitus con insuficiencia cardiaca asociada, identificar los mecanismos que relacionan diabetes mellitus e insuficiencia cardiaca y conocer el manejo de este tipo de pacientes.  Resultados y discusión Los estudios de seguridad cardiovascular EMPAREG-OUTCOME, CANVAS DECLARE-TIMI 58 y CREDENCE, han demostrado que empagliflozina, canagliflozina y dapagliflozina disminuyen el riesgo de eventos cardiovasculares mayores, muerte por causa cardiovascular y reducen el porcentaje de hospitalizaciones por insuficiencia cardiaca. Su mecanismo de acción no está del todo claro, no obstante, sus efectos glucosúricos y natriuréticos resultan potencialmente beneficiosos sobre la presión arterial, peso corporal, remodelado cardiaco y función renal. Estos estudios también señalan la importancia de conocer los efectos secundarios y monitorizarlos para prevenirlos, que, aunque infrecuentes, pueden ocasionar infecciones o amputaciones.  Conclusiones según la evidencia actual, los iSGLT2 constituyen la mejor opción terapéutica en pacientes con diabetes e insuficiencia cardiaca concomitante y aquellos con enfermedad renal crónica (FG entre 30-60 ml/min/1,73 m2), recomendándose además su empleo en aquellos pacientes con insuficiencia cardiaca sin diabetes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction Diabetes mellitus is a metabolic disease whose incidence and prevalence are increase. It produces multiple complications such as atherosclerotic disease and cardiac insufficiency, heart disease, the latter being one of the main causes of death. Diabetes mellitus can lead to heart failure through diabetic cardiomyopathy. For its treatment, sodium-glucose cotransporter type 2 inhibitors stand out. (iSGLT2), drugs that act on the renal proximal convoluted tubule.  Objective to know the impact of iSGLT2 in the treatment of diabetes mellitus with nsufficiency associated heart failure, identify the mechanisms that relate diabetes mellitus and heart failure and know the management of this type of patients.  Results and Discussion Cardiovascular safety studies EMPAREG-OUTCOME, CANVAS DECLARE-TIMI 58 and CREDENCE have shown that empagliflozin, canagliflozin, and dapagliflozin they reduce the risk of major cardiovascular events, death due to cardiovascular causes and reduce the percentage of hospitalizations for heart failure. Its mechanism of action is not entirely clear, however, its glycosuric and natriuretic effects are potentially beneficial on the blood pressure, body weight, cardiac remodeling and renal function. These studies also point out the importance of knowing side effects and monitoring them to prevent them, which, although rare, can cause infections or amputations.  Conclusions according to current evidence, iSGLT2 constitute the best therapeutic option in patients with diabetes and concomitant heart failure and those with chronic kidney disease (GFR between 30-60 ml/min/1.73 m2), also recommending its use in those patients with heart failure without diabetes]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Diabetes Mellitus]]></kwd>
<kwd lng="es"><![CDATA[Nuevos tratamientos]]></kwd>
<kwd lng="es"><![CDATA[Insuficiencia cardiaca]]></kwd>
<kwd lng="es"><![CDATA[inhibidores del cotransportador sodio-glucosa tipo 2]]></kwd>
<kwd lng="en"><![CDATA[Diabetes Mellitus]]></kwd>
<kwd lng="en"><![CDATA[New treatments]]></kwd>
<kwd lng="en"><![CDATA[Heart failure]]></kwd>
<kwd lng="en"><![CDATA[sodium-glucose cotransporter type 2 inhibitors]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Formiga]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Camafort]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Carrasco Sánchez]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heart failure and diabetes: The confrontation of two major epidemics of the 21st century]]></article-title>
<source><![CDATA[Rev Clínica Esp Engl Ed]]></source>
<year>2020</year>
<volume>220</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>135-8</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seferovi&#263;]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Petrie]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Filippatos]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
<name>
<surname><![CDATA[Anker]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Rosano]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bauersachs]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology]]></article-title>
<source><![CDATA[Eur J Heart Fail]]></source>
<year>2018</year>
<volume>20</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>853-72</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saldarriaga-Giraldo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Navas]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Morales]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[De la diabetes a la insuficiencia cardiaca ¿Existe la miocardiopatía diabética?]]></article-title>
<source><![CDATA[Rev Colomb Cardiol]]></source>
<year>2020</year>
<volume>27</volume>
<page-range>12-6</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bell]]></surname>
<given-names><![CDATA[DSH]]></given-names>
</name>
<name>
<surname><![CDATA[Goncalves]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose&#8208;lowering medications]]></article-title>
<source><![CDATA[Diabetes Obes Metab]]></source>
<year>2019</year>
<volume>21</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1277-90</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alarco]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetes e Insuficiencia Cardíaca]]></article-title>
<source><![CDATA[Arch Peru Cardiol Cir Cardiovasc]]></source>
<year>2020</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>6-14</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fitchett]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Udell]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Inzucchi]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heart failure outcomes in clinical trials of glucose&#8208;lowering agents in patients with diabetes]]></article-title>
<source><![CDATA[Eur J Heart Fail]]></source>
<year>2017</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>43-53</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Buse]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Wexler]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Tsapas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rossing]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mingrone]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mathieu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2020</year>
<volume>43</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>487-93</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zelniker]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Braunwald]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2018</year>
<volume>72</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1845-55</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abdul-Ghani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Del Prato]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chilton]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[DeFronzo]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2016</year>
<volume>39</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>717-25</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferrannini]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mark]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mayoux]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CV Protection in the EMPA-REG OUTCOME Trial: A &#8220;Thrifty Substrate&#8221; Hypothesis]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2016</year>
<volume>39</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1108-14</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Neal]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Perkovic]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Mahaffey]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
<name>
<surname><![CDATA[de Zeeuw]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Fulcher]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Erondu]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2017</year>
<volume>377</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>644-57</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Neal]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Perkovic]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Matthews]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Mahaffey]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
<name>
<surname><![CDATA[Fulcher]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Meininger]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial]]></article-title>
<source><![CDATA[Diabetes Obes Metab]]></source>
<year>2017</year>
<volume>19</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>387-93</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perkovic]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Jardine]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Neal]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Bompoint]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Heerspink]]></surname>
<given-names><![CDATA[HJL]]></given-names>
</name>
<name>
<surname><![CDATA[Charytan]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2019</year>
<volume>380</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>2295-306</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wiviott]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Raz]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Bonaca]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Mosenzon]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Kato]]></surname>
<given-names><![CDATA[ET]]></given-names>
</name>
<name>
<surname><![CDATA[Cahn]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2019</year>
<volume>380</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>347-57</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2020</year>
<volume>382</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>972-3</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zelniker]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Wiviott]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Raz]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Im]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Goodrich]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Bonaca]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials]]></article-title>
<source><![CDATA[The Lancet]]></source>
<year>2019</year>
<volume>393</volume>
<numero>10166</numero>
<issue>10166</issue>
<page-range>31-9</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaplan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Abidi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[El-Yazbi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Eid]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Booz]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
<name>
<surname><![CDATA[Zouein]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects]]></article-title>
<source><![CDATA[Heart Fail Rev]]></source>
<year>2018</year>
<volume>23</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>419-37</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sattar]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[McLaren]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kristensen]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Preiss]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[McMurray]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>2016</year>
<volume>59</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1333-9</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lytvyn]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Bjornstad]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Udell]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Lovshin]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Cherney]]></surname>
<given-names><![CDATA[DZI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2017</year>
<volume>136</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>1643-58</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Packer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Anker]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Butler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Filippatos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Zannad]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action]]></article-title>
<source><![CDATA[JAMA Cardiol]]></source>
<year>2017</year>
<volume>2</volume>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
<ref id="B21">
<label>21.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heerspink]]></surname>
<given-names><![CDATA[HJL]]></given-names>
</name>
<name>
<surname><![CDATA[Perkins]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Fitchett]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Husain]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cherney]]></surname>
<given-names><![CDATA[DZI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2016</year>
<volume>134</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>752-72</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baartscheer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Schumacher]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Wüst]]></surname>
<given-names><![CDATA[RCI]]></given-names>
</name>
<name>
<surname><![CDATA[Fiolet]]></surname>
<given-names><![CDATA[JWT]]></given-names>
</name>
<name>
<surname><![CDATA[Stienen]]></surname>
<given-names><![CDATA[GJM]]></given-names>
</name>
<name>
<surname><![CDATA[Coronel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>2017</year>
<volume>60</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>568-73</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23.</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lahnwong]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Potential mechanisms responsible for cardioprotective effects of sodium&#8211;glucose co-transporter 2 inhibitors]]></source>
<year>2018</year>
<page-range>17</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[JHY]]></given-names>
</name>
<name>
<surname><![CDATA[Foote]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Blomster]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Toyama]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Perkovic]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Sundström]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Lancet Diabetes Endocrinol]]></source>
<year>2016</year>
<volume>4</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>411-9</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kluger]]></surname>
<given-names><![CDATA[AY]]></given-names>
</name>
<name>
<surname><![CDATA[Tecson]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[AY]]></given-names>
</name>
<name>
<surname><![CDATA[Lerma]]></surname>
<given-names><![CDATA[EV]]></given-names>
</name>
<name>
<surname><![CDATA[Rangaswami]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lepor]]></surname>
<given-names><![CDATA[NE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Class effects of SGLT2 inhibitors on cardiorenal outcomes]]></article-title>
<source><![CDATA[Cardiovasc Diabetol]]></source>
<year>2019</year>
<volume>18</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B26">
<label>26.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sinha]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ghosal]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Meta-analyses of the effects of DPP-4 inhibitors, GLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure]]></article-title>
<source><![CDATA[Diabetes Res Clin Pract]]></source>
<year>2019</year>
<volume>150</volume>
<page-range>8-16</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27.</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pan]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Zou]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Safety and ef&#64257;ciency of SGLT2 inhibitor combining with insulin in subjects with diabetes]]></source>
<year>2017</year>
<page-range>9</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garg]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Henry]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
<name>
<surname><![CDATA[Banks]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Buse]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Fulcher]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2017</year>
<volume>377</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>2337-48</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
